InsidersTradesSigma
Quantum Genomics Stock: price and insider trades · France · AMF
Track the Quantum Genomics share price and the full insider trade history of the company, a listed issuer based in France. Shares are quoted on FR FR, under the authority of AMF. Operating in the Healthcare & Pharma sector, Quantum Genomics has recorded 1 public disclosures. Market capitalisation: €100.1m. The latest transaction was disclosed on 3 November 2022 (Cession). Among the most active insiders: BAD 21 SPRL. All data is free.
1
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€280,133
1 ops.
Sell Volume
15Σ signal
Fundamental score
Ranked 23,772 of 26,212 companies
21.1
score / 100
Value13
Quality29
FCF yld-9.3%
Earn yld-24%
EV/EBITDA·
ROE·
Gross mgn37%
Net mgn-36%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 3 November 2022
Declarations1 total
722,737 shares@ €0.3876100.0% of flowActionEuronext Growth Paris2022DD869664
1 of 1 declaration
About Quantum Genomics
Quantum Genomics is a French biopharmaceutical company listed on Euronext Growth Paris under ticker ALQGC and ISIN FR0011648971. The company was originally built around academic research originating from leading French institutions, including the Collège de France, INSERM and CNRS, and its mission was to develop a new therapeutic class for cardiovascular diseases. In its initial phase, Quantum Genomics focused on difficult-to-treat and resistant hypertension as well as heart failure, using a differentiated scientific approach based on brain aminopeptidase A inhibition (BAPAI). This mechanism was intended to target blood-pressure regulation through the central nervous system, offering a novel angle in a market dominated by established standard-of-care therapies. Over time, the company’s strategic profile evolved significantly. Following the failure of its REFRESH phase III study for firibastat in October 2022, Quantum Genomics entered a major restructuring phase involving workforce reductions, supplier debt renegotiation and a broader repositioning of the business. During 2023 and 2024, management pursued a strategic reset toward biotechnology and digital health assets, highlighted by a merger project with ExactCure, a French HealthTech company developing artificial-intelligence software designed to adapt medication intake to each individual’s profile. Shareholders approved the key transactions in April 2024, reflecting the company’s intent to shift toward a more diversified model centered on therapeutic optimization and personalized medicine. From a historical standpoint, Quantum Genomics was admitted to trading in 2014, giving it access to capital markets to finance its clinical development programs. The company also pursued international partnering strategies, including agreements in Asia and the Middle East, to support the future development and potential commercialization of its drug candidates. Its headquarters have been in Paris, and it has at times maintained a presence in New York, underlining an international ambition despite its relatively small size. Recent corporate developments have been particularly significant. The company faced severe financial stress, with trading in its shares suspended in October 2024 and a simplified judicial liquidation announced on October 30, 2025 on Euronext. For investors, Quantum Genomics represents a high-risk small-cap biotech story marked by scientific innovation, clinical setbacks, repeated restructurings and a profound strategic transformation over time.
